<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178099</url>
  </required_header>
  <id_info>
    <org_study_id>13746</org_study_id>
    <secondary_id>H7T-MC-TAEJ</secondary_id>
    <nct_id>NCT01178099</nct_id>
  </id_info>
  <brief_title>An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults</brief_title>
  <official_title>A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the exposure to prasugrel's active metabolite and the
      pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel's Active Metabolite, R-138727</measure>
    <time_frame>Time of dosing up to 8 hours post-dose on Day 1 and Day 12</time_frame>
    <description>The AUC of Prasugrel's active metabolite, R-138727, was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) of Prasugrel's Active Metabolite, R-138727</measure>
    <time_frame>Day 1, Day 12</time_frame>
    <description>Cmax was observed from the data and used to calculate Geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>MPA to 5 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] of Prasugrel's Inactive Metabolites, R-95913, R-106583, and R-119251</measure>
    <time_frame>Day 1, Day 12</time_frame>
    <description>AUC was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Residual Platelet Aggregation (RPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>RPA is the percentage aggregation as measured by LTA at 6 minutes after the addition of 5 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Platelet Aggregation (IPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Day 12</time_frame>
    <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline - MPA postbaseline] / MPA at baseline) x 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>MPA to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Residual Platelet Aggregation (RPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>RPA is the percentage aggregation as measured by light transmission aggregometry (LTA) at 6 minutes after the addition of 20 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Day 12</time_frame>
    <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline - MPA postbaseline] / MPA at baseline) x 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Prasugrel's Inactive Metabolites, R-95913, R-106583, and R-119251</measure>
    <time_frame>Day 1, Day 12</time_frame>
    <description>Cmax was observed from the data and used to calculate geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the P2Y12 Reaction Units (PRU) Device Reported P2Y12 Percent Inhibition at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Platelet Reactivity Index (PRI) of Prasugrel at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>PRI was calculated by vasodilator-associated phosphoprotein (VASP) phosphorylation assay using flow cytometry (FC) and a VASP assay using enzyme-linked immunosorbent assay (ELISA). The PRI indicates the level of P2Y12 inhibition. A low PRI reflects strong inhibition of P2Y12, whereas a high PRI reflects weak/absent inhibition of P2Y12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Area Under the Aggregation Curve at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>AUC to 20 micromolar (μM) adenosine diphosphate (ADP), 6.5μM ADP, Collagen, and thrombin receptor activator for peptide 6 (TRAP-6) were calculated by whole blood multi-electrode aggregometry (MEA) assay. Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve, measured in aggregation units*minutes (AU*min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Percent Aggregation to 20 µM Adenosine Diphosphate (ADP) at Day 12</measure>
    <time_frame>Baseline, Day 12</time_frame>
    <description>Percent aggregation was assessed by Plateletworks® ADP assay, a whole blood-based test of platelet aggregation for the assessment of platelet inhibition. The assay determines the change in single platelet count due to activation and aggregation by ADP and inhibition thereof by antiplatelet agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 Reaction Units (PRU)-Derived VerifyNow (VN) Percent Inhibition at Day 12</measure>
    <time_frame>Day 12</time_frame>
    <description>PRU-derived VN percent inhibition is calculated as a percent decrease of PRU from baseline using the following formula:
([PRU at baseline - PRU at time of post baseline] / PRU at baseline) x 100%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Oral, daily for 12 days</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>LY650315</other_name>
    <other_name>CS747</other_name>
    <other_name>Effient</other_name>
    <other_name>Efient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are 50 to 100 kilograms (kg), inclusive, at the time of screening.

          -  Have signed informed consent.

          -  If female, agree to use a reliable method of birth control during the study or are
             women not of child-bearing potential due to surgical sterilization (hysterectomy or
             bilateral oophorectomy or tubal ligation) or menopause.

          -  Control Subjects - Are healthy adults as determined by medical history, physical
             examination, and other screening procedures.

          -  Sickle cell disease (SCD) Subjects - Subjects on hydroxyurea must be on a stable dose
             for the 30 days prior to enrollment without signs of hematologic toxicity at
             screening.

          -  SCD Subjects - Are adults with SCD (hemoglobin SS [HbSS], Hb S beta0 thalassemia, Hb
             SC or Hb S beta+ thalassemia genotype) without a diagnosis of acute vaso-occlusive
             crisis (VOC) requiring medical intervention in an emergency department, infusion
             center, or as an inpatient) within the month prior to screening.

        Exclusion Criteria:

          -  Have a concomitant medical illness (for example, terminal malignancy) that, in the
             opinion of the investigator, is associated with reduced survival over the expected
             treatment period (approximately 1 month).

          -  Exhibit severe hepatic dysfunction (cirrhosis, portal hypertension, or alanine
             aminotransferase [ALT] for aspartate aminotransaminase [AST]≥3 times upper limit of
             normal [ULN]).

          -  Exhibit severe renal dysfunction defined as Cockcroft-Gault creatinine clearance&lt;30
             milliliters per minute (ml/min), or requiring chronic dialysis. Creatine clearance =
             [(140-Age) * Mass (in kg)] \ [72 * Serum creatinine (in milligrams per deciliter
             [mg/dL])].

          -  Exhibit any contraindication for antiplatelet therapy.

          -  Have a history of intolerance or allergy to approved thienopyridines.

          -  Exhibit any signs or symptoms of an infection.

          -  Have a hematocrit &lt;18%.

          -  Exhibit any history of bleeding diathesis, bleeding requiring in-hospital treatment,
             or papillary necrosis.

          -  Have active internal bleeding.

          -  Have a history of spontaneous bleeding requiring in-hospital treatment.

          -  Have gross hematuria or &gt;300 red blood cells (RBC)/high-powered field (HPF) on
             urinalysis at the time of screening.

          -  History of previous intraocular hemorrhage which required treatment with surgery or
             laser, or evidence of active intraocular haemorrhage.

          -  Have a prior history of transient ischemic attack (TIA), ischemic stroke, hemorrhagic
             stroke or other intracranial hemorrhage.

          -  Have a known history of intracranial neoplasm, arteriovenous malformation, or
             aneurysm.

          -  Have clinical findings, in the judgment of the investigator, associated with an
             increased risk of bleeding.

          -  Have an international normalized ratio (INR) known to be &gt;1.5 (INR testing not
             required for study entry).

          -  Have had recent surgery (within 30 days prior to screening) or are scheduled to
             undergo surgery within the next 60 days.

          -  Have a recent history of clinically significant menorrhagia.

          -  Have used any aspirin, warfarin, or thienopyridine in the 10 days prior to enrollment.

          -  Have used any non-aspirin non-steroidal anti-inflammatory drug (NSAID) in the 3 days
             prior to enrollment.

          -  Anticipate using aspirin, warfarin, NSAID, thienopyridine or other antiplatelet agent
             during the study period.

          -  Are women who are known to be pregnant, who have given birth within the past 90 days,
             or who are breastfeeding.

          -  Regular use of drugs of abuse and/or unacceptable positive findings on urinary drug
             screening (a positive urinary drug screening for sleep inducers or pain medications in
             subjects with SCD will be considered as an acceptable finding).

          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical
             trial involving an investigational drug or device or off-label use of a drug or
             device, or are concurrently enrolled in any other type of medical research judged not
             to be scientifically or medically compatible with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317 615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>SE 1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>January 12, 2012</results_first_submitted>
  <results_first_submitted_qc>January 12, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2012</results_first_posted>
  <last_update_submitted>January 12, 2012</last_update_submitted>
  <last_update_submitted_qc>January 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel Healthy Participants</title>
          <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
        </group>
        <group group_id="P2">
          <title>Prasugrel Sickle Cell Disease</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel 10 mg SD; 5 mg MD (Healthy)</title>
          <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by 5 mg/day (for participants&lt;60 kilograms [kg]) for an additional 11 days (multiple dose [MD]).</description>
        </group>
        <group group_id="B2">
          <title>Prasugrel 10 mg SD; 7.5 mg MD (Healthy)</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="B3">
          <title>Prasugrel 10 mg SD; 5 mg MD (Sickle Cell Disease)</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 5 mg/day (for participants&lt;60 kilograms [kg]) for an additional 11 days (MD).</description>
        </group>
        <group group_id="B4">
          <title>Prasugrel 10 mg SD; 7.5 mg MD (Sickle Cell Disease)</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="3.0"/>
                    <measurement group_id="B2" value="27.6" spread="6.5"/>
                    <measurement group_id="B3" value="28.0" spread="14.8"/>
                    <measurement group_id="B4" value="29.6" spread="6.8"/>
                    <measurement group_id="B5" value="27.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel’s Active Metabolite, R-138727</title>
        <description>The AUC of Prasugrel's active metabolite, R-138727, was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
        <time_frame>Time of dosing up to 8 hours post-dose on Day 1 and Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel’s Active Metabolite, R-138727</title>
          <description>The AUC of Prasugrel's active metabolite, R-138727, was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 mg SD (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="57.9" upper_limit="80.5"/>
                    <measurement group_id="O2" value="71.5" lower_limit="60.5" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" lower_limit="42.0" upper_limit="60.5"/>
                    <measurement group_id="O2" value="45.2" lower_limit="37.2" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="30.3" upper_limit="52.3"/>
                    <measurement group_id="O2" value="36.0" lower_limit="27.4" upper_limit="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.829</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 10 mg SD (overall).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.895</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.718</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 7.5 mg MD.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.905</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.656</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 5 mg MD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) of Prasugrel's Active Metabolite, R-138727</title>
        <description>Cmax was observed from the data and used to calculate Geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
        <time_frame>Day 1, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Prasugrel's Active Metabolite, R-138727</title>
          <description>Cmax was observed from the data and used to calculate Geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 mg SD (overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" lower_limit="52.8" upper_limit="87.4"/>
                    <measurement group_id="O2" value="64.7" lower_limit="50.1" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O2" value="38.2" lower_limit="28.4" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="26.9" upper_limit="62.3"/>
                    <measurement group_id="O2" value="42.0" lower_limit="27.6" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.953</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.664</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 10 mg SD (overall).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.612</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.436</ci_lower_limit>
            <ci_upper_limit>0.860</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 7.5 mg MD.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.625</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>MPA to 5 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>MPA to 5 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" spread="23.2"/>
                    <measurement group_id="O2" value="73.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.9" spread="18.7"/>
                    <measurement group_id="O2" value="-33.4" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] of Prasugrel’s Inactive Metabolites, R-95913, R-106583, and R-119251</title>
        <description>AUC was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
        <time_frame>Day 1, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] of Prasugrel’s Inactive Metabolites, R-95913, R-106583, and R-119251</title>
          <description>AUC was calculated through the sampling time of the last quantifiable plasma concentration [AUC(0-tlast)]. Geometric Least Squares (LS) Means were obtained. The log-transformed AUC was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 mg SD (overall) for R-95913</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="42.1" upper_limit="66.1"/>
                    <measurement group_id="O2" value="80.2" lower_limit="63.8" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-95913 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="38.5" upper_limit="63.4"/>
                    <measurement group_id="O2" value="70.9" lower_limit="54.4" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-95913 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="23.1" upper_limit="48.9"/>
                    <measurement group_id="O2" value="47.9" lower_limit="32.9" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mg SD (overall) for R-106583</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" lower_limit="206" upper_limit="300"/>
                    <measurement group_id="O2" value="241" lower_limit="199" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-106583 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="173" upper_limit="263"/>
                    <measurement group_id="O2" value="174" lower_limit="139" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-106583 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="110" upper_limit="207"/>
                    <measurement group_id="O2" value="144" lower_limit="105" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mg SD (overall) for R-119251</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" lower_limit="25.8" upper_limit="41.6"/>
                    <measurement group_id="O2" value="38.3" lower_limit="30.1" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-119251 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="17.1" upper_limit="29.0"/>
                    <measurement group_id="O2" value="23.8" lower_limit="18.0" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-119251 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="13.5" upper_limit="29.9"/>
                    <measurement group_id="O2" value="16.3" lower_limit="11.0" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>This is the estimated value for 10 mg SD (overall) for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
            <estimate_desc>This is the estimated value for 7.5 mg MD for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.918</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.971</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.742</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 10 mg SD (overall) for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.815</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.633</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 7.5 mg MD for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.952</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.658</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>This is the estimated value for the 5 mg MD for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>This is the estimated value for 10 mg SD (overall) for the R-119251 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.779</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>This is the estimated value for 7.5 mg MD for the R-119251 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.813</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.510</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD for the R-119251 metabolite.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Residual Platelet Aggregation (RPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>RPA is the percentage aggregation as measured by LTA at 6 minutes after the addition of 5 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Residual Platelet Aggregation (RPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>RPA is the percentage aggregation as measured by LTA at 6 minutes after the addition of 5 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" spread="29.1"/>
                    <measurement group_id="O2" value="72.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=12, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.3" spread="27.4"/>
                    <measurement group_id="O2" value="-47.3" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of Platelet Aggregation (IPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline – MPA postbaseline] / MPA at baseline) x 100%</description>
        <time_frame>Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation (IPA) to 5 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline – MPA postbaseline] / MPA at baseline) x 100%</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" spread="13.1"/>
                    <measurement group_id="O2" value="41.7" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>MPA to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>MPA to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). The LTA results were collected as MPA, for which low values indicate strong platelet inhibition.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="15.9"/>
                    <measurement group_id="O2" value="73.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=12, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.3" spread="11.7"/>
                    <measurement group_id="O2" value="-30.9" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.219</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Residual Platelet Aggregation (RPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>RPA is the percentage aggregation as measured by light transmission aggregometry (LTA) at 6 minutes after the addition of 20 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Residual Platelet Aggregation (RPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>RPA is the percentage aggregation as measured by light transmission aggregometry (LTA) at 6 minutes after the addition of 20 μM ADP. LTA is an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance).</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" spread="16.7"/>
                    <measurement group_id="O2" value="72.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.0" spread="18.1"/>
                    <measurement group_id="O2" value="-45.5" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.177</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
        <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline – MPA postbaseline] / MPA at baseline) x 100%</description>
        <time_frame>Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12</title>
          <description>IPA is calculated as a percent decrease of maximum platelet aggregation (MPA) from baseline using the following formula:
([MPA at baseline – MPA postbaseline] / MPA at baseline) x 100%</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="13.5"/>
                    <measurement group_id="O2" value="38.5" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Prasugrel's Inactive Metabolites, R-95913, R-106583, and R-119251</title>
        <description>Cmax was observed from the data and used to calculate geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
        <time_frame>Day 1, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Prasugrel's Inactive Metabolites, R-95913, R-106583, and R-119251</title>
          <description>Cmax was observed from the data and used to calculate geometric Least Squares (LS) Means. The log-transformed Cmax was analyzed with a mixed effect model with dose, population, dose*population interaction as fixed effects, and participant as a random effect.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 mg SD (overall) for R-95913</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="23.0" upper_limit="39.8"/>
                    <measurement group_id="O2" value="45.4" lower_limit="34.3" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-95913 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" lower_limit="24.6" upper_limit="45.3"/>
                    <measurement group_id="O2" value="36.3" lower_limit="26.3" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-95913 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="11.7" upper_limit="29.1"/>
                    <measurement group_id="O2" value="34.4" lower_limit="21.8" upper_limit="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mg SD (overall) for R-106583</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="56.3" upper_limit="83.3"/>
                    <measurement group_id="O2" value="59.8" lower_limit="49.0" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-106583 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="45.7" upper_limit="70.6"/>
                    <measurement group_id="O2" value="38.7" lower_limit="30.8" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-106583 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="28.0" upper_limit="53.7"/>
                    <measurement group_id="O2" value="34.8" lower_limit="25.1" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 mg SD (overall) for R-119251</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" lower_limit="20.0" upper_limit="31.1"/>
                    <measurement group_id="O2" value="26.5" lower_limit="21.1" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7.5 mg MD for R-119251 (N=9, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="10.7" upper_limit="22.4"/>
                    <measurement group_id="O2" value="15.9" lower_limit="12.2" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 mg MD for R-119251 (N=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="15.8" upper_limit="25.9"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.7" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
            <estimate_desc>This is the estimated value for 10 mg SD (overall) for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.751</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>This is the estimated value for 7.5 mg MD for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD for the R-95913 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.873</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.660</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>This is the estimated value for 10 mg SD (overall) for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.681</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.886</ci_upper_limit>
            <estimate_desc>This is the estimated value for 7.5 mg MD for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.898</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.612</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD for the R-106583 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.773</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>This is the estimated value for 10 mg SD (overall) for the R-119251 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>0.785</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.582</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>This is the estimated value for 7.5 mg MD for the R-119251 metabolite.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric LS Means, SCD:Healthy</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.648</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
            <estimate_desc>This is the estimated value for 5 mg MD for the R-119251 metabolite.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the P2Y12 Reaction Units (PRU) Device Reported P2Y12 Percent Inhibition at Day 12</title>
        <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the P2Y12 Reaction Units (PRU) Device Reported P2Y12 Percent Inhibition at Day 12</title>
          <description>PRU device reported VerifyNow percent inhibition is reported by Accumetrics VerifyNow™ P2Y12 (VN-P2Y12) assay, a point-of-care device that measures platelet aggregation with single-use, disposable cartridges.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="11.0"/>
                    <measurement group_id="O2" value="1.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=11, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="19.6"/>
                    <measurement group_id="O2" value="47.9" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Platelet Reactivity Index (PRI) of Prasugrel at Day 12</title>
        <description>PRI was calculated by vasodilator-associated phosphoprotein (VASP) phosphorylation assay using flow cytometry (FC) and a VASP assay using enzyme-linked immunosorbent assay (ELISA). The PRI indicates the level of P2Y12 inhibition. A low PRI reflects strong inhibition of P2Y12, whereas a high PRI reflects weak/absent inhibition of P2Y12.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Platelet Reactivity Index (PRI) of Prasugrel at Day 12</title>
          <description>PRI was calculated by vasodilator-associated phosphoprotein (VASP) phosphorylation assay using flow cytometry (FC) and a VASP assay using enzyme-linked immunosorbent assay (ELISA). The PRI indicates the level of P2Y12 inhibition. A low PRI reflects strong inhibition of P2Y12, whereas a high PRI reflects weak/absent inhibition of P2Y12.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percentage PRI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flow Cytometry at Baseline (Day 1), (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.91" spread="10.03"/>
                    <measurement group_id="O2" value="59.36" spread="23.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flow Cytometry, Day 12 Change, (N=12, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.883" spread="22.004"/>
                    <measurement group_id="O2" value="-46.000" spread="27.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ELISA at Baseline (Day 1), (N=11, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.70" spread="2.39"/>
                    <measurement group_id="O2" value="92.03" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ELISA, Day 12 Change (N=11, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.436" spread="17.160"/>
                    <measurement group_id="O2" value="-68.117" spread="12.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>This is the p-value for PRI by flow cytometry. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.679</p_value>
            <p_value_desc>This is the p-value for PRI by ELISA. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Area Under the Aggregation Curve at Day 12</title>
        <description>AUC to 20 micromolar (μM) adenosine diphosphate (ADP), 6.5μM ADP, Collagen, and thrombin receptor activator for peptide 6 (TRAP-6) were calculated by whole blood multi-electrode aggregometry (MEA) assay. Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve, measured in aggregation units*minutes (AU*min).</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Area Under the Aggregation Curve at Day 12</title>
          <description>AUC to 20 micromolar (μM) adenosine diphosphate (ADP), 6.5μM ADP, Collagen, and thrombin receptor activator for peptide 6 (TRAP-6) were calculated by whole blood multi-electrode aggregometry (MEA) assay. Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve, measured in aggregation units*minutes (AU*min).</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>aggregation units*minutes (AU*min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AU*min to 6.5 µM ADP at Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="13.2"/>
                    <measurement group_id="O2" value="106.4" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to 6.5 µM ADP, Day 12 Change (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.538" spread="17.145"/>
                    <measurement group_id="O2" value="-63.182" spread="24.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to 20 µM ADP at Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="19.0"/>
                    <measurement group_id="O2" value="108.1" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to 20 µM ADP, Day 12 Change (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.077" spread="22.552"/>
                    <measurement group_id="O2" value="-66.182" spread="26.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to Collagen at Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="12.7"/>
                    <measurement group_id="O2" value="102.3" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to Collagen, Day 12 Change (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.692" spread="11.707"/>
                    <measurement group_id="O2" value="-3.000" spread="26.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to TRAP-6 at Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="18.6"/>
                    <measurement group_id="O2" value="131.5" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AU*min to TRAP-6, Day 12 Change (N=13, 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.846" spread="20.136"/>
                    <measurement group_id="O2" value="-2.818" spread="33.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.396</p_value>
            <p_value_desc>This is the p-value for AU*min to 6.5 µM ADP. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.288</p_value>
            <p_value_desc>This is the p-value for AU*min to 20 µM ADP. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>This is the p-value for AU*min to Collagen. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>This is the p-value for AU*min to TRAP-6. The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Percent Aggregation to 20 µM Adenosine Diphosphate (ADP) at Day 12</title>
        <description>Percent aggregation was assessed by Plateletworks® ADP assay, a whole blood-based test of platelet aggregation for the assessment of platelet inhibition. The assay determines the change in single platelet count due to activation and aggregation by ADP and inhibition thereof by antiplatelet agents.</description>
        <time_frame>Baseline, Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Percent Aggregation to 20 µM Adenosine Diphosphate (ADP) at Day 12</title>
          <description>Percent aggregation was assessed by Plateletworks® ADP assay, a whole blood-based test of platelet aggregation for the assessment of platelet inhibition. The assay determines the change in single platelet count due to activation and aggregation by ADP and inhibition thereof by antiplatelet agents.</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" spread="9.8"/>
                    <measurement group_id="O2" value="74.0" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 12 (N=12, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.0" spread="16.4"/>
                    <measurement group_id="O2" value="-46.7" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P2Y12 Reaction Units (PRU)-Derived VerifyNow (VN) Percent Inhibition at Day 12</title>
        <description>PRU-derived VN percent inhibition is calculated as a percent decrease of PRU from baseline using the following formula:
([PRU at baseline – PRU at time of post baseline] / PRU at baseline) x 100%</description>
        <time_frame>Day 12</time_frame>
        <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel Healthy Participants</title>
            <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants&lt;60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).</description>
          </group>
          <group group_id="O2">
            <title>Prasugrel Sickle Cell Disease</title>
            <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
          </group>
        </group_list>
        <measure>
          <title>P2Y12 Reaction Units (PRU)-Derived VerifyNow (VN) Percent Inhibition at Day 12</title>
          <description>PRU-derived VN percent inhibition is calculated as a percent decrease of PRU from baseline using the following formula:
([PRU at baseline – PRU at time of post baseline] / PRU at baseline) x 100%</description>
          <population>All participants who received at least 1 dose of the study drug and have evaluable data, excluding participants with an adverse event (AE) of vomiting that occurred at or before 4-hours postdose.</population>
          <units>percent inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="23.4"/>
                    <measurement group_id="O2" value="47.8" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>The p-value is from model: Change from Baseline = Baseline + Treatment + Population + Treatment*Population + Random Error.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel 10/5 mg Healthy Participants</title>
          <description>Participants received a single 10-milligram (mg) dose on Day 1 (single dose [SD]), followed by 5 mg/day (for participants&lt;60 kilograms [kg]) for an additional 11 days (multiple dose [MD]).</description>
        </group>
        <group group_id="E2">
          <title>Prasugrel 10/7.5 mg Healthy Participants</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="E3">
          <title>All Prasugrel Healthy Participants</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="E4">
          <title>Prasugrel 10/5 mg Sickle Cell Disease</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 5 mg/day (for participants&lt;60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="E5">
          <title>Prasugrel 10/7.5 mg Sickle Cell Disease</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
        <group group_id="E6">
          <title>All Prasugrel Sickle Cell Disease Participants</title>
          <description>Participants received a single 10-mg dose on Day 1 (SD), followed by either 5 mg/day (for participants&lt;60 kg) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (MD).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

